JPM vs. NVO: A Head-to-Head Stock Comparison

Updated on November 19, 2025

Here’s a clear look at JPM and NVO, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

JPM is a standard domestic listing, while NVO trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.

Symbol	JPM	NVO
Company Name	JPMorgan Chase & Co.	Novo Nordisk A/S
Country	United States	Denmark
GICS Sector	Financials	Health Care
GICS Industry	Banks	Pharmaceuticals
Market Capitalization	830.73 billion USD	216.69 billion USD
Exchange	NYSE	NYSE
Listing Date	March 17, 1980	April 30, 1981
Security Type	Common Stock	ADR

Historical Performance

This chart compares the performance of JPM and NVO by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

JPM vs. NVO: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	JPM	NVO
5-Day Price Return	-4.83%	5.55%
13-Week Price Return	3.03%	-10.49%
26-Week Price Return	13.07%	-29.53%
52-Week Price Return	24.19%	-59.81%
Month-to-Date Return	-3.46%	-1.55%
Year-to-Date Return	25.31%	-50.17%
10-Day Avg. Volume	7.75M	8.31M
3-Month Avg. Volume	8.10M	7.13M
3-Month Volatility	18.47%	44.27%
Beta	1.09	1.58

Profitability

Return on Equity (TTM)

JPM

16.42%

Banks Industry

Max: 25.75%
Q3: 15.51%
Median: 11.91%
Q1: 8.65%
Min: -1.41%

In the upper quartile for the Banks industry, JPM’s Return on Equity of 16.42% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

NVO

66.95%

Pharmaceuticals Industry

Max: 38.95%
Q3: 20.34%
Median: 11.59%
Q1: 3.32%
Min: -10.91%

NVO’s Return on Equity of 66.95% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

JPM vs. NVO: A comparison of their Return on Equity (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

JPM

33.26%

Banks Industry

Max: 54.20%
Q3: 35.60%
Median: 28.95%
Q1: 22.27%
Min: 2.66%

JPM’s Net Profit Margin of 33.26% is aligned with the median group of its peers in the Banks industry. This indicates its ability to convert revenue into profit is typical for the sector.

NVO

32.88%

Pharmaceuticals Industry

Max: 39.07%
Q3: 19.28%
Median: 13.48%
Q1: 5.73%
Min: -8.86%

A Net Profit Margin of 32.88% places NVO in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

JPM vs. NVO: A comparison of their Net Profit Margin (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

JPM

41.23%

Banks Industry

Max: 63.35%
Q3: 44.30%
Median: 37.14%
Q1: 28.21%
Min: 12.28%

JPM’s Operating Profit Margin of 41.23% is around the midpoint for the Banks industry, indicating that its efficiency in managing core business operations is typical for the sector.

NVO

42.03%

Pharmaceuticals Industry

Max: 45.58%
Q3: 24.35%
Median: 18.05%
Q1: 7.58%
Min: -11.88%

An Operating Profit Margin of 42.03% places NVO in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

JPM vs. NVO: A comparison of their Operating Profit Margin (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	JPM	NVO
Return on Equity (TTM)	16.42%	66.95%
Return on Assets (TTM)	1.33%	21.29%
Net Profit Margin (TTM)	33.26%	32.88%
Operating Profit Margin (TTM)	41.23%	42.03%
Gross Profit Margin (TTM)	--	82.05%

Financial Strength

Current Ratio (MRQ)

JPM

Banks Industry

Max: --
Q3: --
Median: --
Q1: --
Min: --

For the Banks industry, the Current Ratio is often not the most suitable measure of short-term liquidity.

NVO

0.78

Pharmaceuticals Industry

Max: 5.45
Q3: 2.99
Median: 1.98
Q1: 1.29
Min: 0.78

NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

JPM vs. NVO: A comparison of their Current Ratio (MRQ) against their respective Banks and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

JPM

2.95

Banks Industry

Max: 5.78
Q3: 2.55
Median: 0.94
Q1: 0.39
Min: 0.00

The Debt-to-Equity Ratio is often not the primary focus for assessing leverage in the Banks industry.

NVO

0.60

Pharmaceuticals Industry

Max: 1.79
Q3: 0.78
Median: 0.31
Q1: 0.08
Min: 0.00

NVO’s Debt-to-Equity Ratio of 0.60 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

JPM vs. NVO: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Banks and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

JPM

Banks Industry

Max: --
Q3: --
Median: --
Q1: --
Min: --

The Interest Coverage Ratio is often not a primary indicator of debt servicing capacity in the Banks industry.

NVO

149.07

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 10.15
Q1: 2.37
Min: -42.71

With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.

JPM vs. NVO: A comparison of their Interest Coverage Ratio (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	JPM	NVO
Current Ratio (MRQ)	--	0.78
Quick Ratio (MRQ)	--	0.57
Debt-to-Equity Ratio (MRQ)	2.95	0.60
Interest Coverage Ratio (TTM)	--	149.07

Growth

Revenue Growth

JPM vs. NVO: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

JPM vs. NVO: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

JPM

1.94%

Banks Industry

Max: 9.92%
Q3: 5.44%
Median: 3.78%
Q1: 2.38%
Min: 0.00%

JPM’s Dividend Yield of 1.94% is in the lower quartile for the Banks industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.

NVO

3.77%

Pharmaceuticals Industry

Max: 6.72%
Q3: 3.48%
Median: 1.90%
Q1: 0.00%
Min: 0.00%

With a Dividend Yield of 3.77%, NVO offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

JPM vs. NVO: A comparison of their Dividend Yield (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

JPM

27.69%

Banks Industry

Max: 135.42%
Q3: 78.13%
Median: 52.54%
Q1: 35.48%
Min: 0.00%

JPM’s Dividend Payout Ratio of 27.69% is in the lower quartile for the Banks industry. This suggests a conservative dividend policy, with a strategic focus on reinvesting profits for future growth.

NVO

68.98%

Pharmaceuticals Industry

Max: 199.58%
Q3: 85.87%
Median: 49.36%
Q1: 1.12%
Min: 0.00%

NVO’s Dividend Payout Ratio of 68.98% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

JPM vs. NVO: A comparison of their Dividend Payout Ratio (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	JPM	NVO
Dividend Yield (TTM)	1.94%	3.77%
Dividend Payout Ratio (TTM)	27.69%	68.98%

Valuation

Price-to-Earnings Ratio (TTM)

JPM

14.26

Banks Industry

Max: 21.36
Q3: 13.70
Median: 10.55
Q1: 8.08
Min: 2.84

A P/E Ratio of 14.26 places JPM in the upper quartile for the Banks industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

NVO

13.31

Pharmaceuticals Industry

Max: 52.64
Q3: 29.89
Median: 20.77
Q1: 13.37
Min: 5.71

In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 13.31 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

JPM vs. NVO: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

JPM

2.90

Banks Industry

Max: 4.90
Q3: 2.97
Median: 2.24
Q1: 1.58
Min: 0.45

The P/S Ratio is often not a primary valuation tool in the Banks industry.

NVO

4.38

Pharmaceuticals Industry

Max: 8.74
Q3: 4.66
Median: 2.37
Q1: 1.67
Min: 0.11

NVO’s P/S Ratio of 4.38 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

JPM vs. NVO: A comparison of their Price-to-Sales Ratio (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

JPM

2.41

Banks Industry

Max: 2.14
Q3: 1.43
Median: 1.13
Q1: 0.87
Min: 0.25

At 2.41, JPM’s P/B Ratio is at an extreme premium to the Banks industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

NVO

6.88

Pharmaceuticals Industry

Max: 9.86
Q3: 5.28
Median: 2.48
Q1: 1.57
Min: 0.59

NVO’s P/B Ratio of 6.88 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

JPM vs. NVO: A comparison of their Price-to-Book Ratio (MRQ) against their respective Banks and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	JPM	NVO
Price-to-Earnings Ratio (TTM)	14.26	13.31
Price-to-Sales Ratio (TTM)	2.90	4.38
Price-to-Book Ratio (MRQ)	2.41	6.88
Price-to-Free Cash Flow Ratio (TTM)	4.67	21.18